Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.

Author
:
MR Gaudinski
EE Coates
KV Houser
GL Chen
G Yamshchikov
JG Saunders
LA Holman
I Gordon
S Plummer
CS Hendel
M Conan-Cibotti
MG Lorenzo
S Sitar
K Carlton
C Laurencot
RT Bailer
S Narpala
AB McDermott
AM Namboodiri
JP Pandey
RM Schwartz
Z Hu
RA Koup
E Capparelli
BS Graham
Mascola JR
JE Ledgerwood
Team. Study
Abstract
:

VRC01 is a human broadly neutralizing monoclonal antibody (bnMAb) against the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being evaluated in a Phase IIb adult HIV-1 prevention efficacy trial. VRC01LS is a modified version of VRC01, designed for extended serum half-life by increased binding affinity to the neonatal Fc receptor.
Year of Publication
:
2018
Journal
:
PLoS medicine
Volume
:
15
Issue
:
1
Number of Pages
:
e1002493
ISSN Number
:
1549-1277
URL
:
http://dx.plos.org/10.1371/journal.pmed.1002493
DOI
:
10.1371/journal.pmed.1002493
Short Title
:
PLoS Med
Download citation